EDN1 and pulmonary arterial hypertension: Indeed, endothelin-1, NO and prostacyclin pathways are the major molecular pathways involved in the pathogenesis of PAH and represent the targets of all currently approved PAH-specific therapies, as well as for SSc–PAH [50].